Aroa Biosurgery Ltd
ASX:ARX
Aroa Biosurgery Ltd
ASX:ARX
Price:
0.5 AUD
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
ARX
stock under the Base Case scenario is
1.77
AUD.
Compared to the current market price of 0.5 AUD,
Aroa Biosurgery Ltd
is
Undervalued by 72%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ARX
Relative Value
Base Case
1.77
AUD
Undervaluation 72%
Valuation Multiples
Multiples Across Competitors
ARX Competitors Multiples
Aroa Biosurgery Ltd Competitors
Aroa Biosurgery Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NZ |
|
Aroa Biosurgery Ltd
ASX:ARX
|
171.7m AUD | 2.9 | -22.8 | -20.9 | -20.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.6 | 6.8 | 8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 17.9 | 73.4 | 44.9 | 61.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
